| Tyler J Harris, MD | |
|
190 E Bannock St, Boise, ID 83712-6241 | |
| (208) 381-2094 | |
| (208) 381-1791 |
| Full Name | Tyler J Harris |
|---|---|
| Gender | Male |
| Speciality | Diagnostic Radiology |
| Experience | 17 Years |
| Location | 190 E Bannock St, Boise, Idaho |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1275794935 | NPI | - | NPPES |
| 0A1195150 | Medicaid | CA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2085R0202X | Radiology - Diagnostic Radiology | M12086 (Idaho) | Primary |
| 2085R0202X | Radiology - Diagnostic Radiology | A119515 (California) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| St Luke's Regional Medical Center | Boise, ID | Hospital |
| St Luke's Nampa Medical Center | Nampa, ID | Hospital |
| St Luke's Wood River Medical Center | Ketchum, ID | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Boise Radiology Group Pllc | 9638153257 | 53 |
| St Lukes Clinic-treasure Valley Llc | 4981878402 | 968 |
News Archive
Interim study results from STARTversoTM 4 presented today at CROI+ show that 80 percent of hepatitis C (HCV) patients also infected with HIV achieved early treatment success with faldaprevir (BI 201335) combined with pegylated interferon and ribavirin (PegIFN/RBV).
In a significant step toward growing replacement kidneys, researchers at the University of Virginia School of Medicine have identified the cells that give rise to the blood vessels within the kidney. It's a discovery of critical importance, as efforts to grow kidneys have long been frustrated by the inability to create the vasculature necessary for a functional organ.
Scientists have developed a new way to understand complex genetic diseases and have identified a gene that modifies the severity of inherited kidney disease, paving the way for personalised treatments.
The U.S. Food and Drug Administration today approved Xalkori (crizotinib) to treat people with advanced (metastatic) non-small cell lung cancer (NSCLC) whose tumors have an ROS-1 gene alteration. Xalkori is the first and only FDA approved treatment for patients with ROS-1 positive NSCLC.
After a cancer patient receiving an immunotherapy developed encephalitis and died 18 months into treatment, researchers at Vanderbilt-Ingram Cancer Center investigated why the complication occurred, performing a molecular analysis of the disease's pathology and mining data to determine the incidence of similar occurrences.
› Verified 9 days ago
| Entity Name | Boise Radiology Group Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1740216175 PECOS PAC ID: 9638153257 Enrollment ID: O20040614000277 |
News Archive
Interim study results from STARTversoTM 4 presented today at CROI+ show that 80 percent of hepatitis C (HCV) patients also infected with HIV achieved early treatment success with faldaprevir (BI 201335) combined with pegylated interferon and ribavirin (PegIFN/RBV).
In a significant step toward growing replacement kidneys, researchers at the University of Virginia School of Medicine have identified the cells that give rise to the blood vessels within the kidney. It's a discovery of critical importance, as efforts to grow kidneys have long been frustrated by the inability to create the vasculature necessary for a functional organ.
Scientists have developed a new way to understand complex genetic diseases and have identified a gene that modifies the severity of inherited kidney disease, paving the way for personalised treatments.
The U.S. Food and Drug Administration today approved Xalkori (crizotinib) to treat people with advanced (metastatic) non-small cell lung cancer (NSCLC) whose tumors have an ROS-1 gene alteration. Xalkori is the first and only FDA approved treatment for patients with ROS-1 positive NSCLC.
After a cancer patient receiving an immunotherapy developed encephalitis and died 18 months into treatment, researchers at Vanderbilt-Ingram Cancer Center investigated why the complication occurred, performing a molecular analysis of the disease's pathology and mining data to determine the incidence of similar occurrences.
› Verified 9 days ago
| Entity Name | Weiser Valley Hospital District |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1255364030 PECOS PAC ID: 5294704276 Enrollment ID: O20050124000126 |
News Archive
Interim study results from STARTversoTM 4 presented today at CROI+ show that 80 percent of hepatitis C (HCV) patients also infected with HIV achieved early treatment success with faldaprevir (BI 201335) combined with pegylated interferon and ribavirin (PegIFN/RBV).
In a significant step toward growing replacement kidneys, researchers at the University of Virginia School of Medicine have identified the cells that give rise to the blood vessels within the kidney. It's a discovery of critical importance, as efforts to grow kidneys have long been frustrated by the inability to create the vasculature necessary for a functional organ.
Scientists have developed a new way to understand complex genetic diseases and have identified a gene that modifies the severity of inherited kidney disease, paving the way for personalised treatments.
The U.S. Food and Drug Administration today approved Xalkori (crizotinib) to treat people with advanced (metastatic) non-small cell lung cancer (NSCLC) whose tumors have an ROS-1 gene alteration. Xalkori is the first and only FDA approved treatment for patients with ROS-1 positive NSCLC.
After a cancer patient receiving an immunotherapy developed encephalitis and died 18 months into treatment, researchers at Vanderbilt-Ingram Cancer Center investigated why the complication occurred, performing a molecular analysis of the disease's pathology and mining data to determine the incidence of similar occurrences.
› Verified 9 days ago
| Entity Name | North Canyon Medical Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1609046671 PECOS PAC ID: 0941371439 Enrollment ID: O20090409000304 |
News Archive
Interim study results from STARTversoTM 4 presented today at CROI+ show that 80 percent of hepatitis C (HCV) patients also infected with HIV achieved early treatment success with faldaprevir (BI 201335) combined with pegylated interferon and ribavirin (PegIFN/RBV).
In a significant step toward growing replacement kidneys, researchers at the University of Virginia School of Medicine have identified the cells that give rise to the blood vessels within the kidney. It's a discovery of critical importance, as efforts to grow kidneys have long been frustrated by the inability to create the vasculature necessary for a functional organ.
Scientists have developed a new way to understand complex genetic diseases and have identified a gene that modifies the severity of inherited kidney disease, paving the way for personalised treatments.
The U.S. Food and Drug Administration today approved Xalkori (crizotinib) to treat people with advanced (metastatic) non-small cell lung cancer (NSCLC) whose tumors have an ROS-1 gene alteration. Xalkori is the first and only FDA approved treatment for patients with ROS-1 positive NSCLC.
After a cancer patient receiving an immunotherapy developed encephalitis and died 18 months into treatment, researchers at Vanderbilt-Ingram Cancer Center investigated why the complication occurred, performing a molecular analysis of the disease's pathology and mining data to determine the incidence of similar occurrences.
› Verified 9 days ago
| Entity Name | St Lukes Clinic-treasure Valley Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1326336058 PECOS PAC ID: 4981878402 Enrollment ID: O20111119000045 |
News Archive
Interim study results from STARTversoTM 4 presented today at CROI+ show that 80 percent of hepatitis C (HCV) patients also infected with HIV achieved early treatment success with faldaprevir (BI 201335) combined with pegylated interferon and ribavirin (PegIFN/RBV).
In a significant step toward growing replacement kidneys, researchers at the University of Virginia School of Medicine have identified the cells that give rise to the blood vessels within the kidney. It's a discovery of critical importance, as efforts to grow kidneys have long been frustrated by the inability to create the vasculature necessary for a functional organ.
Scientists have developed a new way to understand complex genetic diseases and have identified a gene that modifies the severity of inherited kidney disease, paving the way for personalised treatments.
The U.S. Food and Drug Administration today approved Xalkori (crizotinib) to treat people with advanced (metastatic) non-small cell lung cancer (NSCLC) whose tumors have an ROS-1 gene alteration. Xalkori is the first and only FDA approved treatment for patients with ROS-1 positive NSCLC.
After a cancer patient receiving an immunotherapy developed encephalitis and died 18 months into treatment, researchers at Vanderbilt-Ingram Cancer Center investigated why the complication occurred, performing a molecular analysis of the disease's pathology and mining data to determine the incidence of similar occurrences.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Tyler J Harris, MD Po Box 1108, Corvallis, OR 97339-1108 Ph: (208) 381-2094 | Tyler J Harris, MD 190 E Bannock St, Boise, ID 83712-6241 Ph: (208) 381-2094 |
News Archive
Interim study results from STARTversoTM 4 presented today at CROI+ show that 80 percent of hepatitis C (HCV) patients also infected with HIV achieved early treatment success with faldaprevir (BI 201335) combined with pegylated interferon and ribavirin (PegIFN/RBV).
In a significant step toward growing replacement kidneys, researchers at the University of Virginia School of Medicine have identified the cells that give rise to the blood vessels within the kidney. It's a discovery of critical importance, as efforts to grow kidneys have long been frustrated by the inability to create the vasculature necessary for a functional organ.
Scientists have developed a new way to understand complex genetic diseases and have identified a gene that modifies the severity of inherited kidney disease, paving the way for personalised treatments.
The U.S. Food and Drug Administration today approved Xalkori (crizotinib) to treat people with advanced (metastatic) non-small cell lung cancer (NSCLC) whose tumors have an ROS-1 gene alteration. Xalkori is the first and only FDA approved treatment for patients with ROS-1 positive NSCLC.
After a cancer patient receiving an immunotherapy developed encephalitis and died 18 months into treatment, researchers at Vanderbilt-Ingram Cancer Center investigated why the complication occurred, performing a molecular analysis of the disease's pathology and mining data to determine the incidence of similar occurrences.
› Verified 9 days ago
Jeffrey T Seabourn, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 1055 N Curtis Rd, Boise, ID 83706 Phone: 208-367-2161 | |
Caroline D Sobota, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 1055 N Curtis Rd, Boise, ID 83706 Phone: 208-367-2161 | |
Dr. Chad Eric Sarver, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 500 W Fort St, Boise, ID 83702 Phone: 208-422-1000 | |
Mr. Jesse W Spinner, MD Radiology Medicare: Medicare Enrolled Practice Location: 1055 N Curtis Rd, Boise, ID 83706 Phone: 208-367-2121 Fax: 706-596-6720 | |
Brian Lane Mcmahan, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 190 E Bannock St, Boise, ID 83712 Phone: 208-381-2094 Fax: 208-381-1791 | |
Craig E Leymaster, M.D. Radiology Medicare: Not Enrolled in Medicare Practice Location: 190 E Bannock St, Boise, ID 83712 Phone: 208-381-2094 | |
John A Jackson, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 1055 N Curtis Rd, Boise, ID 83706 Phone: 208-367-2161 |